Breaking News

CTI Acquires Community Research

By Kristin Brooks | February 3, 2014

Adds three locations and expands service offerings

CTI Clinical Trial and Consulting Services (CTI) has acquired Community Research, a specialty clinical research site with three locations throughout Cincinnati, OH. Community Research conducts Phase I-IV trials in various therapeutic areas, including internal medicine, dermatology, psychiatry, and sleep disorders. Its hospital-based Phase I facility can accommodate drug and device trials, with a special focus on first-in-human studies in various patient populations.  Financial terms were not disclosed.
David Mayleben, Ph.D., president and co-founder of Community Research, will serve as vice president at CTI, and will continue to lead the research centers. Co-founder, Dr. Bruce Corser, will serve as a consultant for CTI. Community Research’s 50 employees will join CTI.
“This is a great opportunity to strengthen the offerings that Community Research provides to those in the pharmaceutical and biotechnology industries,” said Dr. Mayleben. “We have worked with CTI many times over the past several years and are excited for this new endeavor.”
“We are looking forward to the integration of both companies and adding the strong operational expertise Community Research has to our own organization,” said Kevin Schwarz, chief operating officer of CTI. “We feel that Community Research provides us with even greater service offerings for our clients, who include more than 70 pharmaceutical and biotechnology companies around the world.”

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials